2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2556

Were Moll and Wright Right?
Abstract Number: 346

What Are We Measuring? Influence of Contextual Factors on RAPID3 Scores in Psoriatic Arthritis
Abstract Number: 2971

What Do Reduced 28 Joint Counts Miss in Patients with Psoriatic Arthritis?
Abstract Number: 131

What Does It Mean to Have Rheumatoid Arthritis Now? a Current Burden of Disease Assessment in the United States
Abstract Number: 1249

What Factors Predict Good Patient Experiences of Switching from Reference Etanercept (EnbrelTM) to an Etanercept Biosimilar (BenepaliTM) in a South West London General Hospital?
Abstract Number: 979

What Have We Learned from Trajectory Analysis of Clinical Outcomes in Osteoarthritis?
Abstract Number: 343

What Is the Impact of Functional Medicine on Patient Reported Outcomes in Inflammatory Arthritis?
Abstract Number: 205

What Is the Value of the Prior Authorization Process in Specialty Drug Therapy?
Abstract Number: 1029

What to Measure after Arthroplasty? Confirmation of a Core Domain Set
Abstract Number: 2484

When Etanercept Switch Fails – Clinical Considerations
Abstract Number: 2514

When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study
Abstract Number: 249

Where to Look for Uric Acid Crystals? Results from a Norwegian Ultrasound Study
Abstract Number: 1174

Which Definition Should be Used to Determine Colchicine Resistance in Patients with Familial Mediterranean Fever?
Abstract Number: 592

Which Imaging Outcomes for AxSpA Are Most Sensitive to Change? a 5-Year Analysis of the DESIR Cohort
Abstract Number: 83

Whole Blood Stimulations Identify Elevated T Cell Cytokines and Altered Granulocyte/Dendritic Cell Signaling in SLE Patients with Variable Disease Activity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].